SEARCH

SEARCH BY CITATION

References

  • 1
    Guichard S, Arnould S, Hennebelle I, Bugat R, Canal P. Combination of oxaliplatin and irinotecan on human colon cancer cell lines: activity in vitro and in vivo. Anticancer Drugs. 2001; 12: 741-751.
  • 2
    van Waardenburg RC, de Jong LA, van Eijndhoven MA, et al. Platinated DNA adducts enhance poisoning of DNA topoisomerase I by camptothecin. J Biol Chem. 2004; 279: 54502-54509.
  • 3
    Tortora G, Ciardiello F, Damiano V, et al. Preclinical and phase I study of oxaliplatin and topotecan in combination in human cancer. Ann Oncol. 2002; 13: 392-398.
  • 4
    Souid AK, Dubowy RL, Blaney SM, et al. Phase I clinical and pharmacologic study of weekly cisplatin and irinotecan combined with amifostine for refractory solid tumors. Clin Cancer Res. 2003; 9: 703-710.
  • 5
    Athale UH, Stewart C, Kuttesch JF, et al. Phase I study of combination topotecan and carboplatin in pediatric solid tumors. J Clin Oncol. 2002; 20: 88-95.
  • 6
    Wells RJ, Reid JM, Ames MM, et al. Phase I trial of cisplatin and topotecan in children with recurrent solid tumors: Children's Cancer Group Study 0942. J Pediatr Hematol Oncol. 2002; 24: 89-93.
  • 7
    Cvitkovic E. Ongoing and unsaid on oxaliplatin: the hope. Br J Cancer. 1998; 77( suppl 4): 8-11.
  • 8
    Dunn TA, Schmoll HJ, Grunwald V, Bokemeyer C, Casper J. Comparative cytotoxicity of oxaliplatin and cisplatin in non-seminomatous germ cell cancer cell lines. Invest New Drugs. 1997; 15: 109-114.
  • 9
    Pendyala L, Creaven PJ. In vitro cytotoxicity, protein binding, red blood cell partitioning, and biotransformation of oxaliplatin. Cancer Res. 1993; 53: 5970-5976.
  • 10
    Riccardi A, Ferlini C, Meco D, Mastrangelo R, Scambia G, Riccardi R. Antitumour activity of oxaliplatin in neuroblastoma cell lines. Eur J Cancer. 1999; 35: 86-90.
  • 11
    Rixe O, Ortuzar W, Alvarez M, et al. Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's anticancer drug screen panel. Biochem Pharmacol. 1996; 52: 1855-1865.
  • 12
    Silvestro L, Anal H, Sommer F, et al. Comparative effects of a new platinum analogue (trans-1-diamine-cyclohexane oxalato-platinum; L-OHP) with CDDP on various cells: correlation with intracellular accumulation [abstract]. Anticancer Res. 1990; 10: 1376. Abstract 115.
  • 13
    Fukuda M, Ohe Y, Kanzawa F, Oka M, Hara K, Saijo N. Evaluation of novel platinum complexes, inhibitors of topoisomerase I and II in non-small cell lung cancer (NSCLC) sublines resistant to cisplatin. Anticancer Res. 1995; 15: 393-398.
  • 14
    Kraker AJ, Moore CW. Accumulation of cis-diamminedichloroplatinum(II) and platinum analogues by platinum-resistant murine leukemia cells in vitro. Cancer Res. 1988; 48: 9-13.
  • 15
    Woynarowski JM, Chapman WG, Napier C, Herzig MC, Juniewicz P. Sequence- and region-specificity of oxaliplatin adducts in naked and cellular DNA. Mol Pharmacol. 1998; 54: 770-777.
  • 16
    Mamenta EL, Poma EE, Kaufmann WK, Delmastro DA, Grady HL, Chaney SG. Enhanced replicative bypass of platinum-DNA adducts in cisplatin-resistant human ovarian carcinoma cell lines. Cancer Res. 1994; 54: 3500-3505.
  • 17
    Raymond E, Faivre S, Woynarowski JM, Chaney SG. Oxaliplatin: mechanism of action and antineoplastic activity. Semin Oncol. 1998; 25: 4-12.
  • 18
    Cosetti M, Wexler LH, Calleja E, et al. Irinotecan for pediatric solid tumors: the Memorial Sloan-Kettering experience. J Pediatr Hematol Oncol. 2002; 24: 101-105.
  • 19
    Vassal G, Couanet D, Stockdale E, et al. Phase II trial of irinotecan in children with relapsed or refractory rhabdomyosarcoma: a joint study of the French Society of Pediatric Oncology and the United Kingdom Children's Cancer Study Group. J Clin Oncol. 2007; 25: 356-361.
  • 20
    Furman WL, Stewart CF, Poquette CA, et al. Direct translation of a protracted irinotecan schedule from a xenograft model to a phase I trial in children. J Clin Oncol. 1999; 17: 1815-1824.
  • 21
    Pappo AS, Lyden E, Breitfeld P, et al. Two consecutive phase II window trials of irinotecan alone or in combination with vincristine for the treatment of metastatic rhabdomyosarcoma: the Children's Oncology Group. J Clin Oncol. 2007; 25: 362-369.
  • 22
    Blaney S, Berg SL, Pratt C, et al. A phase I study of irinotecan in pediatric patients: a Pediatric Oncology Group study. Clin Cancer Res. 2001; 7: 32-37.
  • 23
    Mugishima H, Matsunaga T, Yagi K, et al. Phase I study of irinotecan in pediatric patients with malignant solid tumors. J Pediatr Hematol Oncol. 2002; 24: 94-100.
  • 24
    Turner CD, Gururangan S, Eastwood J, et al. Phase II study of irinotecan (CPT-11) in children with high-risk malignant brain tumors: the Duke experience. Neuro & oncology. 2002; 4: 102-108.
  • 25
    Vassal G, Chastagner P, Doz F, et al. A phase II study of irinotecan (IRI) in children with relapsed or refractory CNS tumors (medulloblastoma and PNET) [abstract]. Proc Am Soc Clin Oncol. 2003; 22. Abstract 805.
  • 26
    Vassal G, Boland I, Santos A, et al. Potent therapeutic activity of irinotecan (CPT-11) and its schedule dependency in medulloblastoma xenografts in nude mice. Int J Cancer. 1997; 73: 156-163.
  • 27
    Houghton PJ, Cheshire PJ, Hallman JD, et al. Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors. Cancer Chemother Pharmacol. 1995; 36: 393-403.
  • 28
    Bomgaars LR, Bernstein M, Krailo M, et al. Phase II trial of irinotecan in children with refractory solid tumors: a Children's Oncology Group study. J Clin Oncol. 2007; 25: 4622-4627.
  • 29
    Zeghari-Squalli N, Raymond E, Cvitkovic E, Goldwasser F. Cellular pharmacology of the combination of the DNA topoisomerase I inhibitor SN-38 and the diaminocyclohexane platinum derivative oxaliplatin. Clin Cancer Res. 1999; 5: 1189-1196.
  • 30
    Becouarn Y, Gamelin E, Coudert B, et al. Randomized multicenter phase II study comparing a combination of fluorouracil and folinic acid and alternating irinotecan and oxaliplatin with oxaliplatin and irinotecan in fluorouracil-pretreated metastatic colorectal cancer patients. J Clin Oncol. 2001; 19: 4195-4201.
  • 31
    Scheithauer W, Kornek GV, Raderer M, et al. Randomized multicenter phase II trial of oxaliplatin plus irinotecan versus raltitrexed as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2002; 20: 165-172.
  • 32
    Wasserman E, Cuvier C, Lokiec F, et al. Combination of oxaliplatin plus irinotecan in patients with gastrointestinal tumors: results of 2 independent phase I studies with pharmacokinetics. J Clin Oncol. 1999; 17: 1751-1759.
  • 33
    Kemeny N, Tong W, Gonen M, et al. Phase I study of weekly oxaliplatin plus irinotecan in previously treated patients with metastatic colorectal cancer. Ann Oncol. 2002; 13: 1490-1496.
  • 34
    Scheithauer W, Kornek GV, Raderer M, et al. Combined irinotecan and oxaliplatin plus granulocyte colony-stimulating factor in patients with advanced fluoropyrimidine/leucovorin-pretreated colorectal cancer. J Clin Oncol. 1999; 17: 902-906.
  • 35
    Kemeny N, Garay CA, Gurtler J, et al. Randomized multicenter phase II trial of bolus plus infusional fluorouracil/leucovorin compared with fluorouracil/leucovorin plus oxaliplatin as third-line treatment of patients with advanced colorectal cancer. J Clin Oncol. 2004; 22: 4701-4709.
  • 36
    Geoerger B, Doz F, Mayer M, et al. Dose-finding and pharmacokinetic study of weekly oxaliplatin in pediatric solid malignancies [abstract]. Proc Am Soc Clin Oncol. 2003; 22. Abstract 3257.
  • 37
    Bomgaars L, Kerr J, Berg S, Kuttesch J, Klenke R, Blaney SM. A phase I study of irinotecan administered on a weekly schedule in pediatric patients. Pediatr Blood Cancer. 2006; 46: 50-55.
  • 38
    Crews KR, Stewart CF, Jones-Wallace D, et al. Altered irinotecan pharmacokinetics in pediatric high-grade glioma patients receiving enzyme-inducing anticonvulsant therapy. Clin Cancer Res. 2002; 8: 2202-2209.
  • 39
    Thompson PA, Gupta M, Rosner GL, et al. Pharmacokinetics of irinotecan and its metabolites in pediatric cancer patients: a report from the Children's Oncology Group. Cancer Chemother Pharmacol. 2008; 62: 1027-1037.
  • 40
    Vassal G, Doz F, Frappaz D, et al. A phase I study of irinotecan as a 3-week schedule in children with refractory or recurrent solid tumors. J Clin Oncol. 2003; 21: 3844-3852.
  • 41
    Ma MK, Zamboni WC, Radomski KM, et al. Pharmacokinetics of irinotecan and its metabolites SN-38 and APC in children with recurrent solid tumors after protracted low-dose irinotecan. Clin Cancer Res. 2000; 6: 813-819.
  • 42
    Falcone A, Masi G, Allegrini G, et al. Biweekly chemotherapy with oxaliplatin, irinotecan, infusional fluorouracil, and leucovorin: a pilot study in patients with metastatic colorectal cancer. J Clin Oncol. 2002; 20: 4006-4014.
  • 43
    Gil-Delgado MA, Bastian G, Guinet F, et al. Oxaliplatin plus irinotecan and FU-FOL combination and pharmacokinetic analysis in advanced colorectal cancer patients. Am J Clin Oncol. 2004; 27: 294-298.
  • 44
    Innocenti F, Undevia SD, Iyer L, et al. Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol. 2004; 22: 1382-1388.
  • 45
    Furman WL, Crews KR, Billups C, et al. Cefixime allows greater dose escalation of oral irinotecan: a phase I study in pediatric patients with refractory solid tumors. J Clin Oncol. 2006; 24: 563-570.
  • 46
    National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE). Version 3.0. NIH Pub. No. 03-5410, 3-9-2006. Bethesda, Md: US Department of Health and Human Services, National Institutes of Health, National Cancer Institute; 2006.
  • 47
    Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000; 92: 205-216.
  • 48
    Spunt SL, Freeman BB,III, Billups CA, et al. Phase I clinical trial of oxaliplatin in children and adolescents with refractory solid tumors. J Clin Oncol. 2007; 25: 2274-2280.
  • 49
    Guzy S, Bauer RJ. Use of the Monte-Carlo parametric expectation maximization (MC-PEM) estimation method with important sampling for very sparse data settings. Clin Pharmacol Ther. 2003; 73: P51-P51.
  • 50
    Stewart CF, Panetta JC, O'Shaughnessy MA, et al. UGT1A1 promoter genotype correlates with SN-38 pharmacokinetics, but not severe toxicity in patients receiving low-dose irinotecan. J Clin Oncol. 2007; 25: 2594-2600.
  • 51
    Goldberg RM, Sargent DJ, Morton RF, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol. 2004; 22: 23-30.
  • 52
    Hoff PM, Saad ED, Pazdur R, et al. Phase I trial of combined irinotecan and oxaliplatin given every 3 weeks to patients with metastatic colorectal cancer. Invest New Drugs. 2004; 22: 307-313.
  • 53
    Graham MA, Lockwood GF, Greenslade D, Brienza S, Bayssas M, Gamelin E. Clinical pharmacokinetics of oxaliplatin: a critical review. Clin Cancer Res. 2000; 6: 1205-1218.
  • 54
    Kuhn JG. Pharmacology of irinotecan. Oncology (Huntington). 1998; 12: 39-42.
  • 55
    Govindan R, Read W, Faust J, Mc LH. Irinotecan and carboplatin in metastatic or recurrent non-small-cell lung cancer. Oncology (Williston Park). 2003; 17: 27-29.
  • 56
    Kern W, Beckert B, Lang N, et al. Phase I and pharmacokinetic study of hepatic arterial infusion with oxaliplatin in combination with folinic acid and 5-fluorouracil in patients with hepatic metastases from colorectal cancer. Ann Oncol. 2001; 12: 599-603.
  • 57
    Reimund JM, Muller CD, Finck G, Escalin G, Duclos B, Baumann R. Factors contributing to infectious diarrhea-associated pancreatic enzyme alterations. Gastroenterol Clin Biol. 2005; 29: 247-253.
  • 58
    Fouladi M, Blaney SM, Poussaint TY, et al. Phase II study of oxaliplatin in children with recurrent or refractory medulloblastoma, supratentorial primitive neuroectodermal tumors, and atypical teratoid rhabdoid tumors: a pediatric brain tumor consortium study. Cancer. 2006; 107: 2291-2297.
  • 59
    Ehrsson H, Wallin I, Yachnin J. Pharmacokinetics of oxaliplatin in humans. Med Oncol. 2002; 19: 261-265.
  • 60
    Ramchandani RP, Wang Y, Booth BP, et al. The role of SN-38 exposure, UGT1A1*28 polymorphism, and baseline bilirubin level in predicting severe irinotecan toxicity. J Clin Pharmacol. 2007; 47: 78-86.
  • 61
    Bomgaars L, Kuttesch N, Bernstein M, Blaney S. Correlation of UGT1A1 promoter genotype with pharmacokinetics and toxicity in pediatric patients receiving irinotecan (CPT-11) [abstract]. Proc Am Soc Clin Oncol. 2003: 22. Abstract 551.